Therapy News and Research

RSS

Women who take fertility drugs are at greater risk to develop thyroid cancer

Women who take the most common fertility drugs, progesterone and clomiphene, are at a greater risk to develop thyroid cancer than those who don't, according to a study by the Institute of Cancer Epidemiology, Danish Cancer Society.

12 Oct 2009

World’s first engineered T cell receptor trial opens with new cellular therapy for HIV

Researchers at Adaptimmune Limited and the University of Pennsylvania School of Medicine, have announced the approval of an Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) and opening for enrolment of the first ever study using patients’ cells carrying an engineered T cell receptor to treat HIV (SL9 HA-GAG-TCR). The trial may have important implications in the development of new treatments for HIV potentially slowing – or even preventing – the onset of AIDS.

11 Oct 2009

Controlled trial comparing Bevacizumab to Ranibizumab finds no difference in efficacy

Investigators from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have shown, at 6 months in a small group of patients, that there is no difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD).

9 Oct 2009

CREON Delayed-Release Capsules improves fat absorption in patients with Cystic Fibrosis

Solvay Pharmaceuticals, Inc. announced that Phase III data published in the Journal of Cystic Fibrosis showed that CREON® (pancrelipase) Delayed-Release Capsules, the most prescribed pancreatic enzyme replacement therapy (PERT) in the United States, significantly improves a key measure of fat absorption in patients with CF who suffer from exocrine pancreatic insufficiency (EPI).

9 Oct 2009

Brookdale Senior Living enters asset purchase agreement with affiliates of Sunrise Senior Living

Brookdale Senior Living Inc. today announced that it has entered into a definitive asset purchase agreement with affiliates of Sunrise Senior Living, Inc.to acquire 21 senior living communities that are currently owned by those affiliates for an aggregate purchase price of $204 million plus customary transaction expenses.

9 Oct 2009

FDA Advisory Committee approves use of Selzentry tablets in combination with HIV therapy

Pfizer Inc. announced today that the U.S. Food and Drug Administration’s (FDA) Antiviral Drugs Advisory Committee voted (10 to 4) to recommend the approval of Selzentry (maraviroc) tablets for use in treatment-naïve adult patients with CCR5-tropic HIV-1 virus as part of combination therapy.

9 Oct 2009

CytoDyn to conduct a study on Cytolin at Massachusetts General Hospital

In response to new economic and regulatory realities, CytoDyn, Inc. has made a sea change in its strategy for developing Cytolin®, the Company’s unique immune therapy for treating HIV/AIDS.

9 Oct 2009

HealthHelp to provide radiation oncology management on national scale

With cancer’s incidence and treatment costs rising, HealthHelp has become the first company to provide radiation oncology management on a national scale. Approximately 4 million Humana patients in 46 states will benefit from this innovative new program.

9 Oct 2009

TargetEx to be the coordinator for CancerGrid consortium

TargetEx llc, Budapest announced today that the Research Directorate General of the Commission of the European Communities approved the transfer of the coordinator responsibilities of the European Cancer Research Consortium (CancerGrid) to TargetEx.

9 Oct 2009

New soy germ-based ingredient improves menopausal symptoms

SE5-OH containing Natural S-equol, a novel soy germ-based ingredient in a supplement, improved menopausal symptoms, including significantly reducing hot flash frequency by nearly 59 percent, according to a peer-reviewed study in Japanese women.

9 Oct 2009

AHF criticizes Pfizer for its current pricing of Selzentry AIDS drug

Responding to today’s news that the Food and Drug Administration (FDA) Antiviral Advisory Committee has approved Pfizer Inc.'s AIDS therapy, Selzentry (maraviroc), for use in therapy-naïve patients, AIDS Healthcare Foundation (AHF) strongly criticized Pfizer for its current pricing of the drug at an Average Wholesale Price (AWP) of $13,767 per-patient per-year—which, if this price remains when use is expanded, would make it the most expensive first-line AIDS drug on the market.

9 Oct 2009

TGen selected to conduct cancer experiments using advanced computer simulations

SAIC-Frederick Inc., under its prime contract with the National Cancer Institute, has named the Translational Genomics Research Institute (TGen) as one of five national centers selected to conduct cancer experiments using advanced computer simulations.

9 Oct 2009

NHLBI grants for diagnosis and treatment of cardiovascular and blood disorders

Two teams led by Massachusetts General Hospital (MGH) researchers, also members of the Harvard Stem Cell Institute (HSCI), are among 18 groups receiving National Heart Lung and Blood Institute (NHLBI) grants for the development of stem-cell based tools and treatments to understand and treat cardiovascular and blood disorders.

9 Oct 2009

Manchester scientists test radioimmunotherapy in early phase clinical trials

MANCHESTER SCIENTISTS are testing an emerging therapy called radioimmunotherapy (RIT) in early phase clinical trials, according to a presentation at the NCRI Cancer Conference in Birmingham today (Wednesday).

9 Oct 2009

Refurbished pacemakers: No complications for patients

Patients who received refurbished pacemakers donated from Detroit area funeral homes survived without complications from the devices, according to a case series reported by the University of Michigan Cardiovascular Center.

9 Oct 2009

Gluten-free diet leads to complete recovery of bone mineralization in CD affected children

Celiac disease (CD) is an inherited intestinal disorder characterized by life-long intolerance to the ingestion of gluten, a protein found in wheat, rye, and barley. Although CD can be diagnosed at any age, it commonly occurs during early childhood (between 9 and 24 months). Reduced bone mineral density is often found in individuals with CD.

9 Oct 2009

NHLBI awards $16.7 million to develop new clinical strategies in stem cell therapy

The National Heart, Lung and Blood Institute has awarded a total of $16.7 million to Irwin Bernstein, M.D., and Beverly Torok-Storb, Ph.D., both members of the Clinical Research Division at Fred Hutchinson Cancer Research Center.

9 Oct 2009

Aging of the immune system coincides with higher rates of cancer in the elderly

Elderly cancer patients need a combination of treatments tailor-made to their specific needs to successfully combat the disease. The challenge is to boost their immune response to cancer vaccines, because like the rest of our organs, our immune system ages and gradually becomes less efficient as we get older.

9 Oct 2009

Therapeutic hypothermia after CPR improves survival and lessens brain damage

Cooling a person's body within six hours of cardiac arrest with successful CPR might improve survival and lessen brain damage, according to a new Cochrane review.

9 Oct 2009

Destructive immune cells gain access to insulin-producing cells and help cause diabetes

St. Jude Children's Research Hospital investigators have discovered how destructive immune cells gain access to insulin-producing cells and help cause diabetes.

9 Oct 2009

Therapy News and Research

Women who take fertility drugs are at greater risk to develop thyroid cancer

World’s first engineered T cell receptor trial opens with new cellular therapy for HIV

Controlled trial comparing Bevacizumab to Ranibizumab finds no difference in efficacy

CREON Delayed-Release Capsules improves fat absorption in patients with Cystic Fibrosis

Brookdale Senior Living enters asset purchase agreement with affiliates of Sunrise Senior Living

FDA Advisory Committee approves use of Selzentry tablets in combination with HIV therapy

CytoDyn to conduct a study on Cytolin at Massachusetts General Hospital

HealthHelp to provide radiation oncology management on national scale

TargetEx to be the coordinator for CancerGrid consortium

New soy germ-based ingredient improves menopausal symptoms

AHF criticizes Pfizer for its current pricing of Selzentry AIDS drug

TGen selected to conduct cancer experiments using advanced computer simulations

NHLBI grants for diagnosis and treatment of cardiovascular and blood disorders

Manchester scientists test radioimmunotherapy in early phase clinical trials

Refurbished pacemakers: No complications for patients

Gluten-free diet leads to complete recovery of bone mineralization in CD affected children

NHLBI awards $16.7 million to develop new clinical strategies in stem cell therapy

Aging of the immune system coincides with higher rates of cancer in the elderly

Therapeutic hypothermia after CPR improves survival and lessens brain damage

Destructive immune cells gain access to insulin-producing cells and help cause diabetes

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News